ASTRAZEN - IntraDay Trade Analysis with Live Signals

Last Updated Time : 20 Dec 25, 07:02 am

IntraDay Trade Rating: 3.5

📊 Analysis: ASTRAZEN trades at ₹9,092, near its DMA 50 (₹9,112) and above DMA 200 (₹8,663), showing medium-term strength but short-term hesitation. RSI at 48.2 is neutral, while MACD (-26.0) indicates bearish divergence. Volume (3,969 vs 2,962 avg) is slightly above average, supporting intraday liquidity. Fundamentals are strong with ROCE 33.4% and ROE 23.6%, though valuation is stretched (P/E 98.3 vs industry 30.6, PEG 2.27). Suitable for cautious intraday trades with disciplined stop-losses.

• 💹 Optimal Buy Price: ₹9,050–9,100 (near support zone)
• 🎯 Profit-Taking Levels: ₹9,180 (first resistance), ₹9,250 (next resistance)
• 🛡️ Stop-Loss: Below ₹9,000 (to protect against breakdown)
• ⏱️ Exit if Holding: Exit intraday if price fails to sustain above ₹9,050 or if RSI slips below 47 with MACD staying negative despite volume support.

Positive

• ✅ Strong ROCE 33.4% and ROE 23.6% reflect efficiency.
• ✅ PAT growth from ₹56.1 Cr. to ₹58.1 Cr. in latest quarter.
• ✅ DII holding increased (+0.71%), showing domestic institutional support.
• ✅ Low debt-to-equity 0.04 ensures financial stability.

Limitation

• ⚠️ High P/E 98.3 vs industry 30.6 indicates premium valuation.
• ⚠️ MACD negative (-26.0), showing bearish divergence.
• ⚠️ PEG ratio 2.27 reflects expensive growth valuation.
• ⚠️ Book value ₹320 vs price ₹9,092 highlights stretched valuation.

Company Negative News

• ❌ FII holding reduced (-0.29%), showing foreign investor caution.
• ❌ Valuation concerns with high P/E and PEG ratio.

Company Positive News

• 🌟 Quarterly profit growth (+51.3%) supports fundamentals.
• 🌟 Strong efficiency metrics (ROCE, ROE) add confidence.
• 🌟 Dividend yield 0.35% supports investor sentiment.

Industry

• 🏗️ Industry PE at 30.6 vs ASTRAZEN PE 98.3 shows sector undervaluation compared to ASTRAZEN.
• 🏗️ Pharma sector remains resilient, supported by healthcare demand and institutional interest.

Conclusion

📌 ASTRAZEN is a moderate intraday candidate with strong fundamentals but stretched valuations and weak technicals. Traders may attempt scalps near ₹9,050–9,100 with profit exits around ₹9,180–9,250, while maintaining a disciplined stop-loss below ₹9,000.

Would you like me to extend this into a pharma sector peer benchmarking overlay so you can compare ASTRAZEN against Sun Pharma, Dr. Reddy’s, and other peers for intraday rotation opportunities?